Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CY-MET-RIC
2023-509042-35-01Phase 2Authorised
- Sponsor
- CHU de Nantes
- Start
- Apr 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of methotrexate and cyclophosphamide in myeloid diseases and lymphoid neoplasm (2 arms), sponsored by CHU de Nantes. Primary endpoint: Incidence of corticosteroid-resistant grade 3–4 acute graft-versus-host disease. Planned start Apr 2024; status: authorised.
02
Drugs
methotrexatecyclophosphamide
03
Conditions
myeloid diseaseslymphoid neoplasm
Beyond the preview
Go deeper on 2023-509042-35-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509042-35-01.